Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAAG: Penpulimab and Anlotinib with Chemo in Metastatic Pancreatic Cancer
NCT05493995Phase 2Completed
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jul 2022
- Primary completion
- May 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of penpulimab and anlotinib in pancreatic adenocarcinoma (PDAC), sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: Objective Response Rate up to 3 years and Disease Control Rate up to 3 years. Started Jul 2022; status: completed.
02
Drugs
penpulimabanlotinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05493995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05493995.